RESMED INC

Company Overview

ResMed Inc. is a global leader in digital health and cloud‑connected medical devices focused on sleep and breathing health and residential care software, selling CPAP/APAP, bilevel and ventilator devices, masks, diagnostic recorders and cloud platforms (AirView, myAir), plus Residential Care Software (Brightree, MatrixCare, MEDIFOX DAN). In FY2025 devices were ~52% of revenue, masks/diagnostics ~36% and Residential Care Software ~12%, with net revenue of $5.15B, gross margin expanding to 59.4% and net income of $1.40B; the business supports >30M cloud‑connected patients and >10M myAir registrations. The company operates across distributed global manufacturing sites and faces material regulatory, reimbursement, IP and supply‑chain risks that directly affect product launches, manufacturing cadence and service revenues.

Executive Compensation Practices

Given ResMed’s mix of durable device sales and a growing recurring software business, executive pay is likely tied to both traditional medical‑device KPIs (revenue growth, device volumes, gross margin and EPS) and software/recurring metrics (ARR, software bookings and subscription retention). Management’s FY2025 emphasis on margin expansion, cash generation and disciplined capital returns (share repurchases and dividends) suggests short‑term incentives incorporate adjusted operating income / adjusted EPS and cash flow or ROIC measures, while long‑term awards will favor equity (RSUs and performance shares) that track TSR, multi‑year EPS/revenue targets and strategic R&D/regulatory milestones. R&D spend (6.4% of revenue), product development (e.g., AirSense 11), clinical trial progress and IP protection are material drivers for retention grants for technical leadership; conversely, safety events, regulatory actions or significant litigation are likely to trigger clawbacks or negative discretion in bonus payout. The company’s use of non‑GAAP metrics in MD&A means some incentive plans may reference adjusted results, so investors should monitor plan disclosures for adjustment policies.

Insider Trading Considerations

Insiders at ResMed will likely concentrate trades around predictable public events—quarterly earnings, major product launches (e.g., AirSense 11), regulatory approvals/clearances, large software contracts or M&A announcements—where material nonpublic information exists and trading is restricted by blackout windows and pre‑clearance requirements. Because executives receive significant equity compensation and the firm executes buybacks and dividends, routine Form 4 activity may reflect tax‑related sales at vesting or exercises, and periodic larger sales can coincide with repurchase campaigns or portfolio diversification. Sector‑specific triggers that can prompt sudden insider activity include adverse field‑safety notices, reimbursement/bid outcomes, supply‑chain disruptions, or major clinical results; these events also raise the likelihood of 10b5‑1 plans being used to provide pre‑scheduled, rule‑compliant trades. Finally, healthcare regulatory oversight (FDA, EU MDR/IVDR), data/privacy obligations (HIPAA, GDPR) and any disclosure of AI‑related product changes create heightened risk of trading restrictions and potential clawback enforcement.